Tirzepatide
Dual GIP / GLP-1 agonist for serious body recomposition.
Tirzepatide is a first-in-class dual incretin — simultaneously activating both GIP and GLP-1 receptors. This dual mechanism produces stronger appetite, glucose, and body-composition effects than GLP-1 alone.
- 99%+ purity
- Third-party tested
- Cold-chain shipping
- Discreet worldwide delivery
- Powerful appetite suppression
- Significant body-composition change
- Improved insulin sensitivity
- Stable energy through the day
Combined GIP + GLP-1 receptor agonism lowers food intake, improves insulin sensitivity, and supports significant body-weight reduction.
Typical research protocol: 2.5–5 mg once weekly, titrated upward every 4 weeks based on tolerance.
For laboratory and research use only. Not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease. All protocols are reference summaries provided for educational purposes — always consult a qualified healthcare professional.